NASDAQ:IMRN Immuron (IMRN) Stock Price, News & Analysis $0.90 +0.02 (+2.78%) Closing price 11/16/2026 04:00 PM EasternExtended Trading$0.88 -0.02 (-2.18%) As of 11/16/2026 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About Immuron Stock (NASDAQ:IMRN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Immuron alerts:Sign Up Key Stats Today's Range$0.82▼$0.9550-Day Range$0.83▼$1.8452-Week Range$0.68▼$1.99Volume23,750 shsAverage Volume17,799 shsMarket Capitalization$7.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Immuron Limited is an Australian biopharmaceutical company that develops and commercializes oral antibody-based products. Its approach uses targeted antibodies intended to bind pathogens or other biological targets in the gastrointestinal tract. The company’s principal commercial product is Travelan, an oral product designed to help prevent travelers’ diarrhea. Immuron also develops investigational therapies for infectious and inflammatory conditions, including candidates focused on Clostridioides difficile infection and other gastrointestinal diseases. Based in Melbourne, Immuron serves customers in Australia and other markets through sales and distribution arrangements. Its activities span commercializing oral health products and advancing its therapeutic candidates through clinical development.AI Generated. May Contain Errors. Read More Immuron Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks23rd Percentile Overall ScoreIMRN MarketRank™: 1.153538584565 of 5 starsImmuron scored higher than 23% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingImmuron has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageImmuron has only been the subject of 1 research reports in the past 90 days.Read more about Immuron's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioImmuron has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.35% of the float of Immuron has been sold short.Short Interest Ratio / Days to CoverImmuron has a short interest ratio ("days to cover") of 1.65, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Immuron has recently decreased by 60.59%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmuron does not currently pay a dividend.Dividend GrowthImmuron does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.73 News SentimentImmuron has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Immuron this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Immuron to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Immuron insiders have not sold or bought any company stock.Percentage Held by Insiders7.01% of the stock of Immuron is held by insiders.Percentage Held by Institutions0.12% of the stock of Immuron is held by institutions.Read more about Immuron's insider trading history. Receive IMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immuron and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMRN Stock News HeadlinesImmuron Engages LifeSci Capital for Strategic InitiativesNovember 10, 2026 | tipranks.comImmuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic InitiativesNovember 10, 2026 | globenewswire.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars. | Behind the Markets (Ad)Emerging Growth Research Reports Continued Revenue Growth at ImmuronNovember 5, 2026 | finance.yahoo.comImmuron CEO to showcase infectious-disease portfolio at Emerging Growth ConferenceOctober 28, 2026 | tipranks.comImmuron continued quarterly sales growthOctober 27, 2026 | globenewswire.comImmuron trims ATM facility to US$2 million while preserving funding flexibilityOctober 26, 2026 | tipranks.comImmuron Cuts U.S. ATM Offering Capacity to $2 Million in Updated F-3 FilingOctober 23, 2026 | tipranks.comSee More Headlines IMRN Stock Analysis - Frequently Asked Questions How have IMRN shares performed this year? Immuron's stock was trading at $0.7680 at the start of the year. Since then, IMRN stock has increased by 17.1% and is now trading at $0.8996. How were Immuron's earnings last quarter? Immuron (NASDAQ:IMRN) announced its quarterly earnings data on Friday, August, 14th. The company reported ($0.08) EPS for the quarter. The business had revenue of $1.27 million for the quarter. When did Immuron IPO? Immuron (IMRN) raised $6 million in an IPO on Friday, June 9th 2017. The company issued 600,000 shares at $9.99 per share. Joseph Gunnar and Rodman & Renshaw (a unit of H.C. Wainwright & Co.) served as the underwriters for the IPO and WallachBeth Capital was co-manager. How do I buy shares of Immuron? Shares of IMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immuron own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immuron investors own include Inovio Pharmaceuticals (INO), Alibaba Group (BABA), GE Aerospace (GE), Sorrento Therapeutics (SRNE), Canopy Growth (CGC), Gilead Sciences (GILD) and CrowdStrike (CRWD). Company Calendar Last Earnings8/14/2026Today11/16/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 IMRN's financial health is in the Yellow zone, according to TradeSmith. IMRN has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IMRN CIK1660046 Webwww.immuron.com.au Phone(138) 892-4854Fax6103 98227735Employees7Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio7.26 Quick Ratio5.98 Sales & Book Value Annual Sales$5.47 million Price / Sales1.33 Cash FlowN/A Price / Cash FlowN/A Book Value$0.94 per share Price / Book0.96Miscellaneous Outstanding Shares8,070,000Free Float7,505,000Market Cap$7.26 million OptionableNot Optionable Beta1.20 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:IMRN) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredA Nasdaq drone company just landed a deal with a Philippine billionaire's groupA Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billio...The Tomorrow Investor | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuron Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuron With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.